E. Ohman J or Asset Management AB Acquires 42,787 Shares of Vera Therapeutics, Inc. $VERA

Key Points

• E. Ohman J or Asset Management AB nearly doubled its Vera Therapeutics stake in the second quarter, adding 42,787 shares to own 85,777 shares valued at approximately $3.68 million. Institutional investors collectively own 99.21% of VERA.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and an average price target of $83.85, despite Wedbush lowering its target to $34 and assigning a neutral rating.
• Vera shares opened at $30.29, down 4.1%, while the company reported a quarterly loss of $1.52 per share—slightly better than estimates. CEO Marshall Fordyce also sold 46,250 shares for about $1.96 million under a pre-arranged trading plan.

E. Ohman J or Asset Management AB grew its holdings in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 99.5% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 85,777 shares of the company's stock after purchasing an additional 42,787 shares during the period. E. Ohman J or Asset Management AB owned about 0.12% of Vera Therapeutics worth $3,681,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Handelsbanken Fonder AB boosted its stake in shares of Vera Therapeutics by 11.6% during the second quarter. Handelsbanken Fonder AB now owns 22,100 shares of the company's stock valued at $948,000 after purchasing an additional 2,300 shares during the period. Janus Henderson Group PLC lifted its holdings in Vera Therapeutics by 26.7% during the 1st quarter. Janus Henderson Group PLC now owns 17,658 shares of the company's stock valued at $710,000 after buying an additional 3,723 shares in the last quarter. ADAR1 Capital Management LLC lifted its holdings in Vera Therapeutics by 8.8% during the 1st quarter. ADAR1 Capital Management LLC now owns 16,033 shares of the company's stock valued at $645,000 after buying an additional 1,300 shares in the last quarter. California State Teachers Retirement System boosted its position in Vera Therapeutics by 31.5% in the 1st quarter. California State Teachers Retirement System now owns 49,737 shares of the company's stock valued at $2,001,000 after buying an additional 11,907 shares during the period. Finally, Royal Bank of Canada boosted its position in Vera Therapeutics by 190.6% in the 1st quarter. Royal Bank of Canada now owns 19,987 shares of the company's stock valued at $804,000 after buying an additional 13,108 shares during the period. 99.21% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

VERA has been the topic of a number of research reports. The Goldman Sachs Group reaffirmed a "buy" rating and set a $90.00 target price on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. Jefferies Financial Group reiterated a "buy" rating and issued a $60.00 price target on shares of Vera Therapeutics in a report on Tuesday, June 2nd. Needham & Company LLC set a $125.00 price objective on Vera Therapeutics in a research note on Wednesday, July 8th. Raymond James Financial restated a "strong-buy" rating and set a $84.00 price objective on shares of Vera Therapeutics in a report on Tuesday. Finally, Wedbush decreased their target price on Vera Therapeutics from $43.00 to $34.00 and set a "neutral" rating for the company in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $83.85.

Vera Therapeutics Trading Down 4.1%

NASDAQ:VERA opened at $30.29 on Wednesday. Vera Therapeutics, Inc. has a one year low of $19.93 and a one year high of $56.05. The company has a debt-to-equity ratio of 0.15, a quick ratio of 13.64 and a current ratio of 13.64. The firm has a market cap of $2.17 billion, a P/E ratio of -5.17 and a beta of 0.92. The firm has a 50-day simple moving average of $36.51 and a 200-day simple moving average of $38.82.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last released its quarterly earnings data on Monday, August 10th. The company reported ($1.52) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.56) by $0.04. During the same quarter in the prior year, the company earned ($1.20) EPS. Equities analysts anticipate that Vera Therapeutics, Inc. will post -6.37 EPS for the current fiscal year.

Insider Buying and Selling

In other Vera Therapeutics news, CEO Marshall Fordyce sold 46,250 shares of the company's stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $42.30, for a total transaction of $1,956,375.00. Following the completion of the sale, the chief executive officer owned 151,994 shares in the company, valued at $6,429,346.20. This represents a 23.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 15.90% of the stock is owned by company insiders.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body's own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source